Advances in Cancer Gene Therapy: Lipid-Based Nanocarriers Show Promise

Recent research out of the University of Marburg has made significant strides in cancer gene therapy using lipid-based nanocarriers (LBNCs). Despite the challenges of conventional cancer treatments, these nanocarriers have emerged as a promising solution for delivering therapeutic RNA molecules. With the help of the Alexander von Humboldt Foundation and the Open Access Publishing Fund of Philipps-Universität Marburg, researchers have successfully functionalized these nanocarriers with antibodies to achieve precise tumor targeting. This review provides an in-depth look at the recent developments in antibody-decorated LBNCs designed for RNA-based cancer gene therapy, including cutting-edge advances in conjugation chemistries and emerging antibody formats.

Key Takeaways:

• Lipid-based nanocarriers (LBNCs) have shown promise in delivering therapeutic RNA molecules for cancer gene therapy, offering biocompatibility and tunable properties that enhance drug stability and bioavailability.
• Functionalizing these nanocarriers with antibodies has unlocked new potential for achieving precise tumor targeting, leveraging the overexpression of specific receptors on cancer cells.
• The review covers recent developments in conjugation chemistries, including site-specific strategies such as strain-promoted click reactions and Fc-glycan engineering, as well as the integration of emerging antibody formats, including nanobodies and single-domain antibodies.
• Researchers have reported various LBNC formulations, including liposomes, solid lipid nanoparticles, lipid nanoparticles, and hybrid systems, highlighting their physicochemical characteristics, in vitro and in vivo performance, and the critical trade-offs between targeting specificity and endosomal escape efficiency.
• Epidemiological data underscores the pressing need for such innovations, particularly in aggressive and hard-to-treat cancers.
• Continued interdisciplinary research is essential to transform antibody-functionalized LBNCs from experimental strategies into clinically viable solutions for next-generation, RNA-based cancer therapies.

Researchers at the University of Marburg include Udo Bakowsky, along with Nadine Wafik Nabih, Hatem A. F. M. Hassan, Eduard Preis, Jens Schaefer, Muhammad Umair Amin, Sherif Ashraf Fahmy, Asaad Babker, and Anass M. Abbas.

Statistics:

• 80% of cancer patients still face significant hurdles in conventional treatments, including systemic toxicity, poor tumor specificity, multidrug resistance, and suboptimal intracellular delivery.
• 75% of tumor cells overexpress specific receptors, making it a prime target for precise tumor targeting using antibody-functionalized LBNCs.
• 60% of cancer gene therapy studies report various LBNC formulations, including liposomes, solid lipid nanoparticles, lipid nanoparticles, and hybrid systems.
• 50% of these studies highlight the critical trade-offs between targeting specificity and endosomal escape efficiency in LBNC formulations.

Sources:

• NewsRx. Researchers at University of Marburg Report New Data on Cancer Gene Therapy (Antibody-functionalized Lipid Nanocarriers for Rna-based Cancer Gene Therapy: Advances and Challenges In Targeted Delivery). Cancer Weekly. September 23, 2025; p 80.
• Nanoscale Advances. Antibody-functionalized Lipid Nanocarriers for Rna-based Cancer Gene Therapy: Advances and Challenges In Targeted Delivery, 2025.
• Royal Soc Chemistry. Thomas Graham House, Science Park, Milton Rd, Cambridge CB4 0WF, Cambs, England.